The strong revenue growth and improved cash flow suggest increasing adoption of LUPKYNIS. The 2026 guidance indicates continued growth momentum. The share repurchases demonstrate confidence in the company's future. Traders should monitor the sustainability of revenue growth and whether future earnings can be maintained without one-time tax benefits.
Price Chart
Executive Summary
Aurinia Pharmaceuticals reported strong financial results for 2025, with total revenue up 20% year-over-year to $283.1 million and net product sales of LUPKYNIS up 25% to $271.3 million. The company posted net income of $287.2 million, driven by a $173 million income tax benefit from releasing its deferred tax asset valuation allowance. For 2026, Aurinia guided for total revenue of $315-$325 million and LUPKYNIS sales of $305-$315 million.
Key Financial Metrics
Key Facts
- Total revenue for 2025 was $283.1 million, up 20% YoY
- Net product sales of LUPKYNIS were $271.3 million, up 25% YoY
- Net income was $287.2 million, up 4852% YoY due to $173 million tax benefit
- Cash flow from operations was $135.7 million, up 206% YoY
- 2026 guidance: total revenue $315-$325 million, LUPKYNIS sales $305-$315 million
- Company repurchased 12.2 million shares for $98.2 million in 2025
Financial Impact
Revenue growth of 20-25% and significant improvement in profitability with 206% increase in operating cash flow
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| LUPKYNIS | $271.3M | +25.0% |
Risk Factors
- 2025 net income was significantly boosted by a one-time $173 million tax benefit
- License, collaboration and royalty revenue declined 38% YoY to $11.7 million
- Future performance depends on continued LUPKYNIS adoption and successful development of aritinercept
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001600620-26-000015 |
| Document: auph-20260226.htm | 0001600620-26-000015 |
| Document: 0001600620-26-000015-index-headers.html | 0001600620-26-000015 |
| Document: 0001600620-26-000015-index.html | 0001600620-26-000015 |
| Document: 0001600620-26-000015.txt | 0001600620-26-000015 |
| CONTEXT: Previous Earnings (2026-02-26) | 0001600620-26-000015 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.13 $16.12 | ▼ −0.06% | ▼ −0.66% | $15.85 (−1.74%) |
Jun 3, 2026 17w ago | Insider Buy | $15.67 $15.80 | ▲ +0.83% | ▲ +1.95% | $15.85 (+1.15%) |
May 11, 2026 20w ago | 8-K | $15.72 $15.78 | ▲ +0.38% | ▲ +0.69% | $15.85 (+0.83%) |
Feb 26, 2026 31w ago | 8-K | $13.97 $14.60 | ▲ +4.51% | ▲ +10.91% | $15.85 (+13.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access